Systemic Lupus Erythematosus Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Systemic Lupus Erythematosus pipeline constitutes 120+ key companies continuously working towards developing 140+ Systemic Lupus Erythematosus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Systemic Lupus Erythematosus Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus Market.

The Systemic Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Systemic Lupus Erythematosus Pipeline Report: https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Systemic Lupus Erythematosus treatment therapies with a considerable amount of success over the years.
• Systemic Lupus Erythematosus companies working in the treatment market are Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others, are developing therapies for the Systemic Lupus Erythematosus treatment
• Emerging Systemic Lupus Erythematosus therapies in the different phases of clinical trials are- Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others are expected to have a significant impact on the Systemic Lupus Erythematosus market in the coming years.
• In February 2026, The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) of Saphnelo (anifrolumab) for subcutaneous use in adult patients with systemic lupus erythematosus (SLE). In response, AstraZeneca submitted the additional information requested in the CRL and remains committed to collaborating with the FDA to advance the application as swiftly as possible.
• In October 2024, The FDA has approved Cullinan Therapeutics' investigational new drug (IND) application for CLN-978, intended to treat systemic lupus erythematosus (SLE).
• In September 2024, Cartesian Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation to Descartes-08 for treating juvenile dermatomyositis (JDM).
• In September 2024, Caribou Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted fast-track designation to its CAR T-cell therapy CB-010 for the treatment of systemic lupus erythematosus (SLE)
• In September 2024, UCB and Biogen announced positive outcomes from their Phase III PHOENYCS GO clinical trial, evaluating dapirolizumab pegol as a treatment for moderate-to-severe systemic lupus erythematosus.
• In August 2024, Conduit Pharmaceuticals announced plans to conduct a Phase IIa clinical trial to assess AZD1656 for treating multiple autoimmune diseases, including systemic lupus erythematosus (SLE).
• In July 2024, The first patient has been treated with Descartes-08 for systemic lupus erythematosus. This therapy was previously used in patients with myasthenia gravis, a chronic autoimmune disorder causing muscle weakness.
• In February 2024, Idorsia Pharmaceuticals has established a significant global research and development partnership with Viatris to advance and commercialize two Phase III assets, selatogrel and cenerimod, worldwide.

Systemic Lupus Erythematosus Overview
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect various parts of the body. In this condition, the immune system mistakenly attacks healthy tissues and organs, leading to inflammation, pain, and damage to different systems within the body.

Get a Free Sample PDF Report to know more about Systemic Lupus Erythematosus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Systemic Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:
• Mosunetuzumab: Roche
• Itolizumab: Equillium/ Biocon Limited
• KPG 818: Kangpu Biopharmaceuticals
• BOS161721: Boston Pharmaceuticals S
• NKTR-358: Nektar Therapeutics
• ABBV-599: AbbVie
• Daxdilimab (VIB7734): Horizon Therapeutics
• SAR441344: Sanofi
• BIIB059: Biogen
• Obinutuzumab: Hoffman-La-Roche

Systemic Lupus Erythematosus Route of Administration
Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Systemic Lupus Erythematosus Molecule Type
Systemic Lupus Erythematosus Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Systemic Lupus Erythematosus Pipeline Therapeutics Assessment
• Systemic Lupus Erythematosus Assessment by Product Type
• Systemic Lupus Erythematosus By Stage and Product Type
• Systemic Lupus Erythematosus Assessment by Route of Administration
• Systemic Lupus Erythematosus By Stage and Route of Administration
• Systemic Lupus Erythematosus Assessment by Molecule Type
• Systemic Lupus Erythematosus by Stage and Molecule Type

DelveInsight's Systemic Lupus Erythematosus Report covers around 140+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Systemic Lupus Erythematosus product details are provided in the report. Download the Systemic Lupus Erythematosus pipeline report to learn more about the emerging Systemic Lupus Erythematosus therapies
https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Systemic Lupus Erythematosus Therapeutics Market include:
Key companies developing therapies for Systemic Lupus Erythematosus are - Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, F. Hoffmann-La Roche AG, Pfizer Limited, ImmuPharma PLC, Bristl Myers Squibb Company, AstraZeneca, Merck & Co., Inc., and others.

Systemic Lupus Erythematosus Pipeline Analysis:
The Systemic Lupus Erythematosus pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Lupus Erythematosus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Lupus Erythematosus Treatment.
• Systemic Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Systemic Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Lupus Erythematosus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Systemic Lupus Erythematosus drugs and therapies
https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Systemic Lupus Erythematosus Pipeline Market Drivers
• Promising Therapeutic Approaches, increasing Awareness of the Disease, recent Advancements in Research and Development are some of the important factors that are fueling the Systemic Lupus Erythematosus Market.

Systemic Lupus Erythematosus Pipeline Market Barriers
• However, obstacles in Systemic Lupus Erythematosus Pipeline, hit and Trial Approach of Researchers, high Annual Cost of Therapies and other factors are creating obstacles in the Systemic Lupus Erythematosus Market growth.

Scope of Systemic Lupus Erythematosus Pipeline Drug Insight
• Coverage: Global
• Key Systemic Lupus Erythematosus Companies: Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others
• Key Systemic Lupus Erythematosus Therapies: Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others
• Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
• Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers

Request for Sample PDF Report for Systemic Lupus Erythematosus Pipeline Assessment and clinical trials

Table of Contents
1. Systemic Lupus Erythematosus Report Introduction
2. Systemic Lupus Erythematosus Executive Summary
3. Systemic Lupus Erythematosus Overview
4. Systemic Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment
5. Systemic Lupus Erythematosus Pipeline Therapeutics
6. Systemic Lupus Erythematosus Late Stage Products (Phase II/III)
7. Systemic Lupus Erythematosus Mid Stage Products (Phase II)
8. Systemic Lupus Erythematosus Early Stage Products (Phase I)
9. Systemic Lupus Erythematosus Preclinical Stage Products
10. Systemic Lupus Erythematosus Therapeutics Assessment
11. Systemic Lupus Erythematosus Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Systemic Lupus Erythematosus Key Companies
14. Systemic Lupus Erythematosus Key Products
15. Systemic Lupus Erythematosus Unmet Needs
16 . Systemic Lupus Erythematosus Market Drivers and Barriers
17. Systemic Lupus Erythematosus Future Perspectives and Conclusion
18. Systemic Lupus Erythematosus Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Systemic Lupus Erythematosus Market
DelveInsight's 'Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Systemic Lupus Erythematosus Epidemiology
DelveInsight's 'Systemic Lupus Erythematosus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.